Predictive methods for assessing the toxicity of drug antitumor therapy in elderly paT ients with breast cancer

Selection of antitumor drug therapy for elderly patients with breast cancer (BC) is a very serious problem. Such patients receive standard therapy less often than younger women, but in many cases this is not justified by any scientific data. At the same time, the cause of death in the elderly is not the cancer itself. In order to determine the appropriateness of prescribing adjuvant and neoadjuvant chemotherapy to elderly women, it is necessary to take into account the benefit-risk ratio. In elderly patients, standard chemotherapy regimens are preferable, and de-escalation of treatment leads to a decrease in survival. To individualize treatment and determine predictors of toxicity, it is advisable to use validated scales and prognostic models.